RecruitingNCT06713616
Comparing ketamine infusions and esketamine for depression
About this title
Read the official source — NCT06713616This study evaluates the effectiveness of Racemic ketamine for people with depression.
Medication studyAges 18+United States
Understand this study
What is this study about?
This study evaluates the effectiveness of Racemic ketamine for people with depression.
Who could participate?
Listed age limits: from 18 years.
- Listed locations
- Milford and 7 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: January 27, 2025
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 400
- Sponsor
- Yale University
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States
- Age range
- Over 18 Years
- Official registry ID
- NCT06713616
- Official title
Show the full official title
Comparative Effectiveness of Racemic Ketamine Versus Esketamine (Spravato®) for Depression
Recruitment & locations
Currently recruitingA study may be recruiting, but some locations may no longer be accepting participants. Confirm availability with the research team.
Milford · New Haven · Atlanta
5 more locations
- Ann Arbor
- Moore
- Nashville
- Bellaire
- Seattle
Interested in joining this study?
Questions about this study
What is this study about?
This study evaluates the effectiveness of Racemic ketamine for people with depression.
Who is behind this study?
The study sponsor is Yale University, a university.
Does this study involve medication?
Yes. The study involves medication, including Racemic ketamine and Spravato (Esketamine).
Who can participate?
Listed age limits: from 18 years.
Is this study still recruiting?
The registry lists this study as recruiting.
